Latest Updates in Lung Cancer Treatment
The most significant recent advances include consolidation durvalumab after chemoradiotherapy for limited-stage SCLC, fam-trastuzumab deruxtecan-nxki for HER2-mutated NSCLC, and expanded immunotherapy combinations for extensive-stage disease.
Non-Small Cell Lung Cancer (NSCLC)
HER2-Mutated NSCLC: Major Breakthrough with Antibody-Drug Conjugates
Fam-trastuzumab deruxtecan-nxki is now the preferred subsequent therapy for metastatic NSCLC with ERBB2 (HER2) mutations after disease progression, based on the DESTINY-Lung01 phase II trial showing a 55% objective response rate and median overall survival of 17.8 months 1.
This agent specifically targets HER2 exon 20 insertion mutations (present in 86% of the study population) and works as an antibody-drug conjugate linking anti-HER2 antibody to a topoisomerase I inhibitor 1.
Ado-trastuzumab emtansine (T-DM1) serves as an alternative "other recommended" option for HER2-mutated NSCLC, though it is not preferred over fam-trastuzumab deruxtecan-nxki 1.
Critical caveat: Switching between agents with similar mechanisms of action at progression is not recommended 1.
For first-line treatment of HER2-mutated NSCLC, standard chemotherapy with or without immunotherapy remains the approach, as immune checkpoint inhibitor monotherapy appears less effective in this molecular subtype 1.
Grade 3 or higher adverse events occurred in 46% of patients on fam-trastuzumab deruxtecan-nxki, with neutropenia (19%) being most common; importantly, two patients died from drug-related interstitial lung disease, requiring vigilant monitoring 1.
Molecular Testing Remains Central
Comprehensive molecular testing to identify actionable mutations is mandatory for all advanced or metastatic NSCLC patients to guide appropriate targeted therapy selection 1.
Testing should specifically evaluate for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, and HER2 alterations before initiating systemic therapy 1.
Small Cell Lung Cancer (SCLC)
Limited-Stage SCLC: Consolidation Immunotherapy Now Standard
Consolidation durvalumab after concurrent chemoradiotherapy is now recommended for limited-stage SCLC patients without disease progression, representing the most impactful recent update based on the phase III ADRIATIC trial 1.
Eligible patients must have stage I-III disease, ECOG performance status 0-1, and no progression after completing concurrent platinum-etoposide chemotherapy with thoracic radiotherapy 1.
This consolidation approach mirrors the successful strategy already established in stage III NSCLC, now extending immunotherapy benefits to the SCLC population 1.
Extensive-Stage SCLC: Immunotherapy Integration
For extensive-stage SCLC with ECOG PS 0-2, first-line treatment now combines platinum-etoposide chemotherapy with immunotherapy (typically atezolizumab or durvalumab) 1.
Patients with ECOG PS 3-4 due to SCLC should receive carboplatin or cisplatin plus etoposide for 4 cycles; if performance status improves, consider maintenance immunotherapy 1.
For patients whose performance status improves after initial chemotherapy, concurrent or sequential radiotherapy followed by consolidation durvalumab should be considered 1.
Resected SCLC
- Adjuvant cisplatin or carboplatin plus etoposide remains the standard approach for completely resected SCLC 1.
Adjuvant Therapy Advances for Early-Stage NSCLC
Osimertinib has been approved for adjuvant treatment of EGFR-mutated resectable NSCLC, representing a major shift from chemotherapy-only approaches 2.
Atezolizumab and pembrolizumab are now approved as adjuvant immunotherapy for selected patients with resectable NSCLC, typically those with PD-L1 expression ≥1% 2.
Key Clinical Pitfalls to Avoid
Never initiate immunotherapy in HER2-mutated NSCLC as monotherapy without prior chemotherapy, as this molecular subtype shows reduced responsiveness to checkpoint inhibitors alone 1.
Do not use fam-trastuzumab deruxtecan-nxki as first-line therapy for HER2-mutated NSCLC; reserve it for post-progression treatment 1.
Monitor vigilantly for interstitial lung disease in patients receiving fam-trastuzumab deruxtecan-nxki, as fatal cases have occurred 1.
Ensure molecular testing is completed before starting any systemic therapy for advanced NSCLC to avoid missing targetable mutations 1.
For limited-stage SCLC, durvalumab consolidation should only be offered to patients who have not progressed after chemoradiotherapy and maintain adequate performance status 1.